Please note, this OEL/ADE monograph also applies to trifluoperazine hydrochloride (CAS RN 440-17-5). Trifluoperazine hydrochloride (HCl) is indicated for use in treatment of generalized nonpsychotic anxiety disorders and depressive symptoms secondary to anxiety and agitation. It is also indicated for use in the management of schizophrenia (2, 3). It is marketed as a generic drug. Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain. This depresses the release of hypothalamic and hypophyseal hormones and is thought to depress the reticular activating system, thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Trifluoperazine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.